TY - JOUR
T1 - Oral treatment with a rattlesnake native polypeptide crotamine efficiently inhibits the tumor growth with no potential toxicity for the host animal and with suggestive positive effects on animal metabolic profile
AU - Campeiro, Joana D.
AU - Marinovic, Marcelo P.
AU - Carapeto, Fernando Cintra
AU - Dal Mas, Caroline
AU - Monte, Gabriela Guilherme
AU - Carvalho Porta, Lucas
AU - Nering, Marcela B.
AU - Oliveira, Eduardo B.
AU - Hayashi, Mirian A.F.
N1 - Funding Information:
Funding The authors would like to thank for the use of multiuser facility at INFAR for the Leica TCS SP8 confocal microscope (Leica Microsystem, Wetzlar, Germany) use, and we also thank the executive secretary Rosemary Alves de Oliveira for the great administrative support. This work was supported by the São Paulo Research Foundation (Fundação de Amparo à Pesquisa do Estado de São Paulo-FAPESP nos. 2013/13392-4 and 2017/02413-1), and the National Council of Technological and Scientific Development (Conselho Nacional de Desenvolvimento Científico e Tecnológico-CNPq nos. 311815/2012-0, 475739/2013-2 and 39337/2016-0). JDC and MPM receive a fellowship from CAPES, while CDM and GGM are fellowship recipients from CNPq. LCP was supported by a fellowship from FAPESP no. 2015/08812-0.
Funding Information:
We thank Prof. Gilles Landman for the important discussions and support for histopathological analysis. The authors declare that they have no conflict of interest. The authors would like to thank for the use of multiuser facility at INFAR for the Leica TCS SP8 confocal microscope (Leica Microsystem, Wetzlar, Germany) use, and we also thank the executive secretary Rosemary Alves de Oliveira for the great administrative support. This work was supported by the S?o Paulo Research Foundation (Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo-FAPESP nos. 2013/13392-4 and 2017/02413-1), and the National Council of Technological and Scientific Development (Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico-CNPq nos. 311815/2012-0, 475739/2013-2 and 39337/2016-0). JDC and MPM receive a fellowship from CAPES, while CDM and GGM are fellowship recipients from CNPq. LCP was supported by a fellowship from FAPESP no. 2015/08812-0.
Publisher Copyright:
© 2017, Springer-Verlag GmbH Austria, part of Springer Nature.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - The efficacy of crotamine as antitumoral was first demonstrated by daily intraperitoneal (IP) injections of low doses of this toxin in an animal model bearing melanoma tumors. Significant inhibition of tumor growth and increased lifespan of mice bearing tumor was also noticed after 21 consecutive days of this daily IP administration of crotamine. However, due to the limited acceptance of treatments by IP route in clinical conditions, herein, we evaluated the antitumor effect of this native polypeptide employing the oral route. The efficacy of crotamine in inhibiting the melanoma growth in vivo, even after passing through the gastrointestinal tract of the animal, was confirmed here. In addition, biochemical biomarkers and also histopathological analysis showed both the absence of any potential toxic effects in tissues or organs of the animal in which the highest accumulation of crotamine is expected. Interestingly, a reduction of weight gain was observed mainly in animals with tumor treated with crotamine by IP route, but not by oral administration. Albeit, oral administered crotamine was able to significantly decrease the body weight gain of healthy animals without tumor. Taking advantage of this same experimental animal models receiving crotamine by oral route, it was possible to show metabolic changes as the increased capacity of glucose clearance, which was accompanied by a reduction of the total cholesterol, and by increased high-density lipoprotein levels, both observed mainly in the absence of tumor. Triglycerides and low-density lipoprotein were also significantly decreased, but only in the absence of tumor. Taken together, these data suggest a clear trend for metabolic positive effects and mischaracterize unhealthy condition of animals, with or without tumors, treated with crotamine for 21 days. In addition, this study confirmed the efficacy of crotamine administered by oral route as antitumor agent, which besides the additional advantage of administration convenience and decreased risk of toxic effects, allowed the serendipitous observation of several positive metabolic effects on treated animals.
AB - The efficacy of crotamine as antitumoral was first demonstrated by daily intraperitoneal (IP) injections of low doses of this toxin in an animal model bearing melanoma tumors. Significant inhibition of tumor growth and increased lifespan of mice bearing tumor was also noticed after 21 consecutive days of this daily IP administration of crotamine. However, due to the limited acceptance of treatments by IP route in clinical conditions, herein, we evaluated the antitumor effect of this native polypeptide employing the oral route. The efficacy of crotamine in inhibiting the melanoma growth in vivo, even after passing through the gastrointestinal tract of the animal, was confirmed here. In addition, biochemical biomarkers and also histopathological analysis showed both the absence of any potential toxic effects in tissues or organs of the animal in which the highest accumulation of crotamine is expected. Interestingly, a reduction of weight gain was observed mainly in animals with tumor treated with crotamine by IP route, but not by oral administration. Albeit, oral administered crotamine was able to significantly decrease the body weight gain of healthy animals without tumor. Taking advantage of this same experimental animal models receiving crotamine by oral route, it was possible to show metabolic changes as the increased capacity of glucose clearance, which was accompanied by a reduction of the total cholesterol, and by increased high-density lipoprotein levels, both observed mainly in the absence of tumor. Triglycerides and low-density lipoprotein were also significantly decreased, but only in the absence of tumor. Taken together, these data suggest a clear trend for metabolic positive effects and mischaracterize unhealthy condition of animals, with or without tumors, treated with crotamine for 21 days. In addition, this study confirmed the efficacy of crotamine administered by oral route as antitumor agent, which besides the additional advantage of administration convenience and decreased risk of toxic effects, allowed the serendipitous observation of several positive metabolic effects on treated animals.
KW - Crotamine
KW - Melanoma tumor
KW - Metabolism
KW - Oral administration
KW - Snake toxin
UR - https://www.scopus.com/pages/publications/85037719929
UR - https://www.scopus.com/pages/publications/85037719929#tab=citedBy
U2 - 10.1007/s00726-017-2513-3
DO - 10.1007/s00726-017-2513-3
M3 - Article
C2 - 29235017
AN - SCOPUS:85037719929
SN - 0939-4451
VL - 50
SP - 267
EP - 278
JO - Amino Acids
JF - Amino Acids
IS - 2
ER -